Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al

Leukemia volume 19, pages 2333–2334 (2005)Cite this article

TO THE EDITOR

In their letter to the editor, Leguay et al1 present the clinical and molecular characteristics of two patients affected by chronic myeloid leukemia (CML) and treated with imatinib. These two patients showed an aggressive clinical course: they developed resistance to the drug and died soon after the evolution to blast crisis (BC: one lymphoid, one myeloid). Sequencing analysis of the Abl catalytic domain of samples taken during relapse showed the presence of mutation D276G in both cases. Thus, the authors conclude that mutation D276G could be linked to an aggressive disease course and a rapid transformation to acute phase, associated with a particularly poor prognosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Leguay T, Desplat V, Marit G, Mahon F . D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients. Leukemia, (in press).

  2. Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to imatinib. Leukemia 2005; 19: 132–134.

    Article  CAS  Google Scholar 

  3. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55–60.

    Article  CAS  Google Scholar 

  4. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093–2098.

    Article  CAS  Google Scholar 

  5. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. S. Gerardo Hospital, University of Milano Bicocca, Monza, Italy

    R G Piazza, V Magistroni & C Gambacorti-Passerini

  2. Section of Hematology, S. Gerardo Hospital, Monza, Italy

    A Franceschino

  3. Department of Oncology, McGill University, Montreal, Canada

    C Gambacorti-Passerini

Authors
  1. R G Piazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Magistroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Franceschino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Gambacorti-Passerini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Gambacorti-Passerini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piazza, R., Magistroni, V., Franceschino, A. et al. Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al. Leukemia 19, 2333–2334 (2005). https://doi.org/10.1038/sj.leu.2403994

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403994

Search

Advanced search

Quick links